RETR(Osteomyelitis)
1 other identifier
observational
50
1 country
1
Brief Summary
This is a retrospective study describing the management of osteomyelitis in a referece center, with success and failures.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started May 2023
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 15, 2021
CompletedFirst Posted
Study publicly available on registry
June 23, 2021
CompletedStudy Start
First participant enrolled
May 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2025
CompletedApril 13, 2023
May 1, 2022
1 year
June 15, 2021
April 12, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (11)
rate of osteomyelitis in BJI
proportion of patients having had an osteomyelitis
between 2017 and 2021
site of osteomyelitis
localisation
between 2017 and 2021
bone defect size
dimension of the bone defect size
between 2017 and 2021
type of osteomyelitis
hematogenous or after a trauma or after a surgery
between 2017 and 2021
rate of bacteria involved in osteomyelitis
description of bacteria responsible for osteomyelitis
between 2017 and 2021
Description of patients
comorbidities, age
between 2017 and 2021
Description of the follow up of the patients
duration of the follow up of patients
between 2017 and 2021
description of patients : medical treatment
description and duration of antibiotics
between 2017 and 2021
Description of patients : surgical treatment
description of surgery performed
between 2017 and 2021
rate of patient treated with CERAMENT
proportion of patients having had CERAMENT
between 2017 and 2021
rate of treatment failure
treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin
between 2017 and 2021
Study Arms (1)
patients having had an osteomyelitis since 2017
Interventions
description of osteomyelitis and their management
Eligibility Criteria
Patients who presented with osteomyelitis between 2017 and 2021 managed at the CRIOAc Lyon
You may qualify if:
- Patients who presented with osteomyelitis between 2017 and 2021
You may not qualify if:
- Patients who objected to participating in the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hospices Civils de Lyon
Lyon, 69004, France
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 15, 2021
First Posted
June 23, 2021
Study Start
May 1, 2023
Primary Completion
May 1, 2024
Study Completion
May 1, 2025
Last Updated
April 13, 2023
Record last verified: 2022-05